For research use only. Not for human or veterinary use. Supplied as a lyophilized powder for laboratory research.
TB-500 thymosin beta 4 is a naming pair that causes confusion in research ordering. Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein, N-terminally acetylated, first sequenced from calf thymus in 1981 [1][2]. It is described as the major actin-sequestering molecule in eukaryotic cells [3]. In the scientific literature, “TB-500” names a 7-residue synthetic fragment of Tβ4 (Ac-LKKTETQ) [4]. MFP’s “TB-500 (Thymosin Beta-4)” is full-length Tβ4, as its certificate identifiers show.
What is TB-500? How the name is used
- Literature usage: a 2012 drug-testing paper identified TB-500 as the N-terminally acetylated 17–23 fragment of Tβ4, Ac-LKKTETQ [4].
- Market usage: many research suppliers use “TB-500” for full-length thymosin beta-4.
- MFP’s material: the certificate for lot DPS-2022011 (Horizon Analytical; purity 99.38%; quantity 9.93 mg; analysis date 08/14/2026) lists CAS 77591-33-4, formula C₂₁₂H₃₅₀N₅₆O₇₈S and a molecular weight of about 4963 g/mol. These match the PubChem record for full-length thymosin beta-4 (CID 16132341), not the fragment (CID 62707662, C₃₈H₆₈N₁₀O₁₄, ~889 g/mol).
A 2026 review warns that the fragment and the full-length protein are frequently conflated without validated equivalence [5]. Check the formula and molecular weight on any certificate before assuming two “TB-500” products are interchangeable.
Thymosin beta-4 structure and sequence
| Property | Full-length thymosin beta-4 | “TB-500” fragment (literature) |
|---|---|---|
| Length | 43 residues (mature protein) [1][2] | 7 residues (Tβ4 17–23) [4] |
| N-terminus | Acetylserine [2] | Acetylated leucine [4] |
| Formula | C₂₁₂H₃₅₀N₅₆O₇₈S (PubChem 16132341) | C₃₈H₆₈N₁₀O₁₄ (PubChem 62707662) |
| Molecular weight | ~4963 g/mol (PubChem); Mr 4982 reported in 1982 [2] | ~889 g/mol (PubChem) |
| Isoelectric point | 5.1 [1][2] | Not reported here |
UniProt entry P62328 lists the human gene product at 44 residues including the initiator methionine, which is removed in the mature 43-residue protein.
Thymosin beta-4 research: what has been studied
- Actin binding: Tβ4 sequesters G-actin and is studied as a regulator of the cytoskeleton [3].
- Cell migration: reviews report that Tβ4 promotes cell migration, including stem and progenitor cell mobilization, in experimental models [6].
- Repair models: Tβ4 is released by platelets and macrophages after injury and has been studied in dermal, corneal, cardiac and central nervous system repair models, including reduced myofibroblast numbers [3][6].
- Early immunology: the original papers described induction of terminal deoxynucleotidyl transferase in mouse thymocytes [1][2].
These findings come from cell and animal research and reviews; they do not establish effects in people.
Comparison with BPC-157
The only head-to-head study found is an exploratory 32-rat Achilles tendon study, in which the authors’ “synthetic thymosin beta-4 (TB-500)” group showed better biomechanical and histology scores than controls [7]. See BPC-157 vs TB-500.
Regulatory status
- Thymosin beta-4 is not FDA-approved for any indication [5].
- FDA’s Category 2 list of bulk drug substances that may present significant safety risks names “Thymosin beta-4, fragment (LKKTETQ)” [8]. Full-length Tβ4 was not found on that list when it was reviewed for this article.
- Analytical detection of the fragment has been developed for anti-doping testing [4].
Frequently asked questions
In scientific papers, TB-500 is a 7-residue fragment of Tβ4 [4]. Some suppliers use the name for the full 43-residue protein. MFP’s TB-500 certificate identifies full-length thymosin beta-4.
The mature protein is 43 amino acids with an acetylated N-terminus [1][2].
It binds actin and is studied for its roles in cell migration and tissue repair in experimental models [3][6].
Mostly in vitro and rodent studies of thymosin beta-4. A 2026 review found no musculoskeletal evidence in people beyond those models [5].
Research materials and certificates
- TB-500 (Thymosin Beta-4) · BPC-157 + TB-500 Bundle
- Lot certificates: COA Library
- Related: BPC-157 Research · How to Read a Peptide COA
References
- Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162-6. doi:10.1073/pnas.78.2.1162. PMID: 6940133
- Low TL, Goldstein AL. Chemical characterization of thymosin beta 4. J Biol Chem. 1982;257(2):1000-6. PMID: 7054160
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-9. doi:10.1016/j.molmed.2005.07.004. PMID: 16099219
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. doi:10.1002/dta.1402. PMID: 22962027
- Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg. 2026 (online ahead of print). doi:10.5435/JAAOS-D-26-00049. PMID: 42937313
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID: 22074294
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. doi:10.52312/jdrs.2026.2951. PMID: 42542926
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Content current as of 04/22/2026. fda.gov
Research-use-only disclaimer: All products from My Freedom Peptides are supplied as a lyophilized powder for laboratory research. They are for research use only and not for human or veterinary use. My Freedom Peptides LLC is a chemical supplier. It is not a 503A compounding pharmacy or a 503B outsourcing facility. These statements have not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease.
